{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:20Z","timestamp":1788262160051,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.clml.2017.01.001","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T14:32:19Z","timestamp":1484058739000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A\u00a0Multicenter Prospective Observational Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Tomasz","family":"Sacha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"G\u00f3ra-Tybor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"W\u0105sak-Szulkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomira","family":"Kyrcz-Krzemie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"M\u0119dra\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4820-0629","authenticated-orcid":false,"given":"Rafa\u0142","family":"Becht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Bober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Kotowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"W\u0105c\u0142aw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.01.001_bib1","series-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia, v.4","author":"National Comprehensive Cancer Network","year":"2013"},{"key":"10.1016\/j.clml.2017.01.001_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.01.001_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.01.001_bib4","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.01.001_bib5","first-page":"1097","article-title":"Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison","volume":"21","author":"Philips","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2017.01.001_bib6","series-title":"Adherence to Long-Term Therapies: Evidence for Action","author":"Sabate","year":"2003"},{"key":"10.1016\/j.clml.2017.01.001_bib7","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.01.001_bib8","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.01.001_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and nonadherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clml.2017.01.001_bib10","first-page":"1006","article-title":"Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment","volume":"20","author":"Trivedi","year":"2014","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clml.2017.01.001_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Health care resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2017.01.001_bib12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the p210 BCR-ABL gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.clml.2017.01.001_bib13","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.01.001_bib14","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.01.001_bib15","series-title":"TASIGNA (nilotinib) [summary of product characteristics]","year":"2014"},{"key":"10.1016\/j.clml.2017.01.001_bib16","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1185\/03007995.2012.705264","article-title":"A\u00a0retrospective analysis of therapy adherence in\u00a0imatinib resistant or intolerant patients with chronic myeloid leukemia receiving\u00a0nilotinib or dasatinib in a real-world setting","volume":"28","author":"Gu\u00e9rin","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2017.01.001_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1185\/03007995.2011.649849","article-title":"Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia","volume":"28","author":"Yood","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2017.01.001_bib18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.01.001_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00434800","article-title":"The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules. EORTC Study Group on Quality of Life","volume":"2","author":"Sprangers","year":"1993","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2017.01.001_bib20","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S0959-8049(97)10076-4","article-title":"Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients","volume":"34","author":"McLachlan","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2017.01.001_bib21","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2017.01.001_bib22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/07347332.2012.761323","article-title":"Validation of the polish version of the EORTC QLQ-C30 and the QLQ-OG25 for the assessment of health-related quality of life in patients with esophagi-gastric cancer","volume":"31","author":"Tomaszewski","year":"2013","journal-title":"J\u00a0Psychosoc Oncol"},{"key":"10.1016\/j.clml.2017.01.001_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2017.01.001_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000345722","article-title":"Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort","volume":"130","author":"de Almeida","year":"2013","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2017.01.001_bib25","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study","volume":"107","author":"Efficace","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2017.01.001_bib26","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2147\/PPA.S70712","article-title":"Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians","volume":"8","author":"Kek\u00e4le","year":"2014","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clml.2017.01.001_bib27","doi-asserted-by":"crossref","unstructured":"Tsang JP, Rudychev I, Pescatore SL. ASCO 2006 June 2-6, 2006, Atlanta, GA; Part 1, Vol. 24, No. 18S, J Clin Oncol 2006; 24:330s. Abstract 6119.","DOI":"10.1200\/jco.2006.24.18_suppl.6119"},{"key":"10.1016\/j.clml.2017.01.001_bib28","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A\u00a0systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2017.01.001_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1185\/03007990802619425","article-title":"The Adherence Estimator: a brief proximal screener for propensity\u00a0to adhere to medications for chronic disease","volume":"25","author":"McHorney","year":"2009","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:02Z","timestamp":1761870542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016309168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S2152265016309168"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.01.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A\u00a0Multicenter Prospective Observational Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}